Paragraph

TARGET2-Securities Annual Report 2023

Retrieved on: 
Dienstag, Mai 28, 2024
CPMI, IDS, Crisis, Recycling, Risk, Bank of France, INSV, Information services, Inbound, Data warehouse, Central bank, Risk management, CSG, GDP, PFMI, Microsoft Edge, IIA, ECB, DCA, CLM, DB2, Schedule 7, Paragraph, DKK, EOD, RTGS, MIB, EUR, Coronavirus, Software, RTS, Reproduction, ISO, Security (finance), Central Waqf Council, European Central Bank, COVID-19, DWH, TIPS, Framework agreement, Settlement, Statistics, Deutsche Bundesbank, Safety, TARGET2, Incidents, ISSN, KPI, TSRC, Policy, Annual report, Environment, DVP, PDF, Support, TARGET, CDAD, Website, Punctuality, Rural sociology, API, Council, DWP, OJ, Guideline, Bulgarian National Bank, ECMS, Exercise, Overalls, NCBS, Bank statement, Self-assessment, FMI, CSDR, International Organization (journal), Lawyer, DCAS, Classification, SOD, Committee, ISAE, FOP, NCB, Medical imaging

It takes a chronological approach by first discussing the Commission’s legislative proposals of April 2023 against the pre-reform set of fiscal rules, before assessing the final political agreement which has materialised in the revised set of rules.

Key Points: 
  • It takes a chronological approach by first discussing the Commission’s legislative proposals of April 2023 against the pre-reform set of fiscal rules, before assessing the final political agreement which has materialised in the revised set of rules.
  • This paper argues that completing the architecture of Economic and Monetary Union (EMU) is an important missing element and should remain a policy priority.

Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine Prod

Retrieved on: 
Dienstag, Mai 14, 2024
NYU Langone Health, Patient, Takeda, Judgement, Consent, Justice, Risk, Patent, Dialysis, Settlement, Rheumatology, Kidney, FDA, Colchicine, License, Action, MD, Paragraph, ACR, Chronic pain, American College, District court, Vexatious litigation, PALO, Pharmaceutical industry

The Action arose from Scilex’s filing of a revised label with the FDA seeking to expand the label for its FDA-approved liquid colchicine product, Gloperba®, a preventive treatment for gout.

Key Points: 
  • The Action arose from Scilex’s filing of a revised label with the FDA seeking to expand the label for its FDA-approved liquid colchicine product, Gloperba®, a preventive treatment for gout.
  • As part of the Settlement Agreement, the Scilex Parties entered into a License Agreement with Takeda granting the Company and its affiliates a non-exclusive license to certain patents owned by Takeda.
  • With the resolution of this patent issue, Scilex Pharma believes that it has satisfied all requirements for final FDA approval of the expanded Gloperba® label.
  • For more information on Scilex Holding Company, refer to www.scilexholding.com
    For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com .

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

Retrieved on: 
Mittwoch, April 24, 2024
Core, FDA, Ipsen, Food, Pancreatic cancer, Oxaliplatin, RNA, Webcast, Patent, ADC, District court, Fluorouracil, Patient, Paragraph, Dicarboxylic acid, DSM-IV codes, Therapy, CER1, Growth, Pharmaceutical industry

“The delivery of our strategic plan continues to be evidenced by a strong top line, supported by the success of the growth platforms and the increased contribution of the new medicines.

Key Points: 
  • “The delivery of our strategic plan continues to be evidenced by a strong top line, supported by the success of the growth platforms and the increased contribution of the new medicines.
  • Moreover, the pipeline continues to deliver, illustrated this quarter by the regulatory approval in the U.S. of Onivyde as a first-line treatment for pancreatic cancer.
  • “This year marks a pivotal period for our growth plans, with the launches of four new medicines or indications.
  • In April 2024, Ipsen announced an exclusive global licensing agreement for STRO-003, an antibody-drug conjugate (ADC) targeting the ROR1 tumor antigen.

REPLY S.p.A.: Shareholders’ Meeting Approves the 2023 Financial Statements

Retrieved on: 
Dienstag, April 23, 2024
Technology, Finance, Apps, Applications, Consulting, Professional Services, Artificial Intelligence, IOT (Internet of Things), Networks, Data Analytics, Internet, Fintech, Data Management, Security, Consumer Electronics, COVID, Federico, STAR, MTA, Financial statement, Documentation, Shareholder, Record, Paragraph, Acquisition, Remuneration, EXM, Alternative, Share repurchase, Legislature, TUF

The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] today approved the Financial Statements for the financial year 2023, confirming the distribution of a gross dividend of €1.00 per share.

Key Points: 
  • The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] today approved the Financial Statements for the financial year 2023, confirming the distribution of a gross dividend of €1.00 per share.
  • The Reply Group closed the 2023 financial year with a consolidated turnover of €2,118.0 million, recording a 12.0% increase compared to €1,891.1 million in 2022.
  • (owner of a 39.754% shareholding in Reply S.p.A.), which obtained the highest number of votes (63.821% of votes obtained).
  • The Shareholders' Meeting also approved Sections I and II of the Remuneration Report drafted pursuant to Article 123-ter of Legislative Decree 58/1998.

EQS-News: REPLY: The Board of Directors approved the draft financial statements for the year 2023

Retrieved on: 
Mittwoch, April 10, 2024
Automation, EXM, EUR, COVID, Paragraph, Growth, Intelligence, Internet, Artificial intelligence, STAR, AI, MTA, Insurance, Reply, Cloud computing, Cryptocurrency

Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2023, which will be submitted for approval to the Shareholders’ Meeting to be held on first call in Turin on 23 April 2024.

Key Points: 
  • Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2023, which will be submitted for approval to the Shareholders’ Meeting to be held on first call in Turin on 23 April 2024.
  • The Reply Group closed 2023 with a consolidated turnover of €2,118.0 million, an increase of 12.0% compared to €1.891.1 million in 2022.
  • As at 31 December 2023, the Group’s net financial position has been positive at €204.9 million (€70.6 million at 31 December 2022).
  • As at 30 September 2023, the net financial position was positive at €189.7 million.

Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchici

Retrieved on: 
Mittwoch, März 20, 2024
Paragraph, Gout, Vexatious litigation, Shanda, Chronic pain, Settlement, PALO, Justice, Takeda, License, FDA, Federal Trade Commission, Nursing

That litigation arose from Scilex’s filing of a sNDA with the FDA seeking to expand the label for its FDA-approved liquid colchicine product, Gloperba®, a preventive treatment for gout.

Key Points: 
  • That litigation arose from Scilex’s filing of a sNDA with the FDA seeking to expand the label for its FDA-approved liquid colchicine product, Gloperba®, a preventive treatment for gout.
  • As part of the Settlement Agreement, the Scilex Parties entered into a License Agreement with Takeda granting the Company and its affiliates a non-exclusive license to certain patents owned by Takeda.
  • The Settlement Agreement is subject to approval by the district court, and by both the Federal Trade Commission and the U.S. Department of Justice, as is required in Paragraph IV patent case settlements.
  • For more information on Scilex Holding Company, refer to www.scilexholding.com .

REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 2023.

Retrieved on: 
Mittwoch, März 13, 2024
IOT (Internet of Things), Manufacturing, Retail, Other Technology, Artificial Intelligence, Finance, Internet, Data Management, Professional Services, Technology, Mobile, Wireless, Other Energy, Utilities, Other Communications, Energy, Other Retail, Other Manufacturing, Communications, Automation, EXM, COVID, Paragraph, Growth, Intelligence, Artificial intelligence, STAR, AI, MTA, Insurance, Reply, Cloud computing, Cryptocurrency

The Reply Group closed 2023 with a consolidated turnover of €2,118.0 million, an increase of 12.0% compared to €1.891.1 million in 2022.

Key Points: 
  • The Reply Group closed 2023 with a consolidated turnover of €2,118.0 million, an increase of 12.0% compared to €1.891.1 million in 2022.
  • As at 31 December 2023, the Group’s net financial position has been positive at €204.9 million (€70.6 million at 31 December 2022).
  • As at 30 September 2023, the net financial position was positive at €189.7 million.
  • In a short time, we will be living in a union of automation, artificial intelligence, digital interfaces and connected objects.

Brevo Launches Customer Data Platform, Enhanced AI features and Mobile Push Notifications

Retrieved on: 
Dienstag, Februar 13, 2024
Human voice, EST, Firefox, Behavior, CDP, Headline, Elevate, Paragraph, CRM, Creativity, CX

In addition, Brevo is announcing new AI functions, expanding capabilities to better understand customer habits and drive personalized multi-channel campaigns at scale.

Key Points: 
  • In addition, Brevo is announcing new AI functions, expanding capabilities to better understand customer habits and drive personalized multi-channel campaigns at scale.
  • Many marketers rely on retargeting and legacy data management platforms based on segments fed with third-party data.
  • Brevo CDP unifies and manages customer data across the whole tech stack.
  • Using a new Push dashboard for Brevo segments and lists, Brevo customers can drive action and create a seamless customer experience from within the Brevo ecosystem.

Notice Regarding Commencement of Tender Offer for Benesse Holdings, Inc. (Securities Code: 9783) by Bloom 1 K.K.

Retrieved on: 
Montag, Januar 29, 2024
Publishing, Communications, Other Education, Managed Care, Continuing, University, Preschool, Health, Primary, Secondary, Education, Financial instrument, Multimedia, Bloom, Tender, Paragraph, Graduation, Order

We hereby announce today that the attached press release issued by Bloom 1 K.K.

Key Points: 
  • We hereby announce today that the attached press release issued by Bloom 1 K.K.
  • titled “Notice Regarding Commencement of Tender Offer for Benesse Holdings, Inc. (Securities Code: 9783)” has been released.
  • (the Offeror) to Benesse Holdings, Inc. (the Target Company of the Tender Offer).
  • Notice Regarding Commencement of Tender Offer for Benesse Holdings, Inc. (Securities Code: 9783) dated January 29, 2024
    View source version on businesswire.com: https://www.businesswire.com/news/home/20240126441982/en/

Press release - Parliament concerned about the rule of law in Slovakia

Retrieved on: 
Mittwoch, Januar 17, 2024
Special, European Parliament, Legislation, Paragraph, Television, European, Corruption, Government, Language, Crime, Fraud, Environment, Parliament, General officer, Non-governmental organization, RTVS

Need to protect the rule of law

Key Points: 
  • Need to protect the rule of law
    MEPs are particularly concerned about the unjustified use of a fast-track procedure for the criminal code reform and the dissolution of the Special Prosecutor’s Office that handles corruption cases and serious crimes.
  • These changes threaten the integrity of judicial processes and undermine the EU’s fight against fraud according to MEPs.
  • MEPs stress that any criminal law reform must ensure the continuation of ongoing criminal cases and the effectiveness of new ones.
  • Parliament is very concerned by plans to adopt legislation undermining the civic space, restricting the work of NGOs and stigmatising organisations receiving foreign funding.